Neither were published and Pliva was so excited about the results it abandoned the drug entirely One Phase I safety and pharmacokinetics trial of oral BPC-157, registered in 2015, that has no public results and appears to have been withdrawn or abandoned Three small and nonrandomized uncontrolled pilot studies from a single for-profit clinic in Florida, which included a 16-patient knee-pain chart review, a 12-woman interstitial cystitis study, and a small intravenous safety study One legitimate entry: a registered Phase 2 trial of BPC-157 for acute hamstring strain
Injections are daily
Retatrutide is an unapproved investigational triple agonist (GLP-1, GIP, glucagon receptors) not licensed by the MHRA, EMA, or FDA for routine clinical use
Recalls & Warnings August 29, 2017 FDA Warns Seller of Supplements for Allergies, Joint Pain, Bone Health, and More On August 16, 2017, the FDA issued a warning letter to Total Nutrition, Inc
Drug Testing and Analysis